Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery.

The accurate prediction of protein-ligand binding free energies remains a significant challenge of central importance in computational biophysics and structure-based drug design. Multiple recent advances including the development of greatly improved protein and ligand molecular mechanics force fields, more efficient enhanced sampling methods, and low-cost powerful GPU computing clusters have enabled accurate and reliable predictions of relative protein-ligand binding free energies through the free energy perturbation (FEP) methods. However, the existing FEP methods can only be used to calculate the relative binding free energies for R-group modifications or single-atom modifications and cannot be used to efficiently evaluate scaffold hopping modifications to a lead molecule. Scaffold hopping or core hopping, a very common design strategy in drug discovery projects, is critical not only in the early stages of a discovery campaign where novel active matter must be identified but also in lead optimization where the resolution of a variety of ADME/Tox problems may require identification of a novel core structure. In this paper, we introduce a method that enables theoretically rigorous, yet computationally tractable, relative protein-ligand binding free energy calculations to be pursued for scaffold hopping modifications. We apply the method to six pharmaceutically interesting cases where diverse types of scaffold hopping modifications were required to identify the drug molecules ultimately sent into the clinic. For these six diverse cases, the predicted binding affinities were in close agreement with experiment, demonstrating the wide applicability and the significant impact Core Hopping FEP may provide in drug discovery projects.

[1]  B. Roux,et al.  Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. , 2006, Biophysical journal.

[2]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[3]  D. Timm,et al.  Preparation and biological evaluation of conformationally constrained BACE1 inhibitors. , 2015, Bioorganic & medicinal chemistry.

[4]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[5]  Edward D Harder,et al.  How To Deal with Multiple Binding Poses in Alchemical Relative Protein–Ligand Binding Free Energy Calculations , 2015, Journal of chemical theory and computation.

[6]  N. Haginoya,et al.  Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[7]  Hongyu Zhao,et al.  Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. , 2007, Drug discovery today.

[8]  Woody Sherman,et al.  Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation , 2016, ACS omega.

[9]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[10]  B. Berne,et al.  Replica exchange with solute scaling: a more efficient version of replica exchange with solute tempering (REST2). , 2011, The journal of physical chemistry. B.

[11]  Jennifer L. Knight,et al.  Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. , 2015, Journal of the American Chemical Society.

[12]  B. Berne,et al.  Replica exchange with solute tempering: a method for sampling biological systems in explicit water. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  David L Mobley,et al.  Alchemical free energy methods for drug discovery: progress and challenges. , 2011, Current opinion in structural biology.

[14]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[15]  Wei Yang,et al.  Random walk in orthogonal space to achieve efficient free-energy simulation of complex systems , 2008, Proceedings of the National Academy of Sciences.

[16]  Jennifer L. Knight,et al.  Modeling Local Structural Rearrangements Using FEP/REST: Application to Relative Binding Affinity Predictions of CDK2 Inhibitors. , 2013, Journal of chemical theory and computation.

[17]  Lingle Wang,et al.  On achieving high accuracy and reliability in the calculation of relative protein–ligand binding affinities , 2012, Proceedings of the National Academy of Sciences.

[18]  Christophe Chipot,et al.  Good practices in free-energy calculations. , 2010, The journal of physical chemistry. B.

[19]  Emilio Gallicchio,et al.  Advances in all atom sampling methods for modeling protein-ligand binding affinities. , 2011, Current opinion in structural biology.

[20]  Charles H. Bennett,et al.  Efficient estimation of free energy differences from Monte Carlo data , 1976 .

[21]  J. Mongan,et al.  Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. , 2004, The Journal of chemical physics.

[22]  Shuai Liu,et al.  Is Ring Breaking Feasible in Relative Binding Free Energy Calculations? , 2015, J. Chem. Inf. Model..

[23]  Thierry O Fischmann,et al.  Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode. , 2012, ACS medicinal chemistry letters.

[24]  Daniel Cappel,et al.  Accurate Binding Free Energy Predictions in Fragment Optimization , 2015, J. Chem. Inf. Model..

[25]  Benoît Roux,et al.  Free Energy Simulations: Thermodynamic Reversibility and Variability , 2000 .

[26]  H. Berendsen,et al.  Interaction Models for Water in Relation to Protein Hydration , 1981 .

[27]  T. Shibano,et al.  DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles , 2008, Journal of thrombosis and haemostasis : JTH.

[28]  W. L. Jorgensen,et al.  Improved Peptide and Protein Torsional Energetics with the OPLS-AA Force Field , 2015, Journal of chemical theory and computation.

[29]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[30]  Robert Abel,et al.  Sensitivity in binding free energies due to protein reorganization , 2016, bioRxiv.

[31]  A. Mark,et al.  Avoiding singularities and numerical instabilities in free energy calculations based on molecular simulations , 1994 .

[32]  Xin Chen,et al.  A β-tryptase inhibitor with a tropanylamide scaffold to improve in vitro stability and to lower hERG channel binding affinity. , 2012, Bioorganic & medicinal chemistry letters.

[33]  K. Gajiwala,et al.  Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance , 2016, Nature Communications.

[34]  W. L. Jorgensen The Many Roles of Computation in Drug Discovery , 2004, Science.

[35]  Michael P Eastwood,et al.  Minimizing thermodynamic length to select intermediate states for free-energy calculations and replica-exchange simulations. , 2009, Physical review. E, Statistical, nonlinear, and soft matter physics.

[36]  B. Roux,et al.  Computations of standard binding free energies with molecular dynamics simulations. , 2009, The journal of physical chemistry. B.

[37]  R. Copeland,et al.  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat. , 2016, Journal of medicinal chemistry.